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Abstract 
The objective of the present study was to develop a simple, specific and accurate reverse phase high performance 
liquid chromatographic method for the determination of Canagliflozin in bulk and pharmaceutical dosage forms. The 
method is optimized on an inertsil ODS-3(250×4.6mm, 5µ) column with a mobile phase combination of 0.02% Formic 
acid: Acetonitrile (40:60) at a flow rate 1.2ml/min and the eluents were monitored at 230nm. Under these LC conditions 
Canagliflozin peak was eluted at 4.4 min. The developed method was validated as per ICH guidelines. The calibration 
curve was linear over a concentration range of 10-50µg/ml (R
2 
=0.999) and the mean percentage assay was found to be 
98.2. The statistical data proved that proposed method is accurate, precise and reproducible. The method which is LC-MS 
compatible can be adopted in the routine analysis of Canagliflozin in bulk and pharmaceutical dosage forms. 
Keywords: Canagliflozin, RP-HPLC Method development, Method validation. 
 
1. Introduction 
Canagliflozin is an antidiabetic drug used to 
improve glycemic control in patients with type 2 diabetes. 
Canagliflozin is an inhibitor of subtype 2 sodium-glucose 
transport protein (SGLT2) which is responsible for at least 
90% of the glucose reabsorption in the kidney (SGLT1) 
being responsible  for the remaining 10%). Canagliflozin is 
chemically known as (2S, 3R, 4R, 5S, 6R)-2-{3-[5-[4-
Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-
hydroxy methyl-tetrahydro-pyran-3, 4, 5-triol. Literature 
review revealed that there were several analytical methods 
like HPLC [1-6], LC-MS [7], UV spectroscopy [8], HPTLC 
[9] and only few RP-HPLC methods were reported for the 
estimation of Canagliflozin in bulk and tablet dosage forms 
and these methods used non-volatile buffers which reduces 
column efficiency. Hence the present work aimed at the 
development of a new sensitive, accurate and precise RP-
HPLC method for the estimation of Canagliflozin in bulk 
and tablet dosage forms and by using mobile phase that is 
compatible with LC-MS and to validate the same as per 
ICH guidelines [10-12]. 
 
 
 
 
Structure of canagliflozin 
 
2. Experimental Section 
2.1 Materials and Methods 
2.1.1 Chemicals and reagents  
Canagliflozin procured from LAURUS LABS Pvt 
Ltd., Hyderabad and marketed Canagliflozin tablets 
Invokana (B-NO: FLZSN00), was bought from a local 
pharmacy with a labelled amount of 100mg. Methanol, 
Acetonitrile, Water, Formic acid, other chemicals and 
reagent used were of HPLC grade. 
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2.1.2 Equipment 
A Shimadzu prominence HPLC system provide 
with LC-10AT binary pump, SIL-20AHT auto sampler, and 
SPD-10A UV detector was used. Data acquisition was 
carried out using LC solutions software. 
2.2 Chromatographic conditions  
Inertsil ODS-3 column (250×4.6mm, 5µ) and a 
mobile phase consisting of 0.02% Formic acid and 
acetonitrile in the ratio of 40:60 (v/v) at a flow rate of 
1.2ml/min were employed. For quantitative analytical 
purpose, the eluents were monitored by the UV detector at a 
wavelength of 230nm with an injection volume of 10µl and 
maintaining ambient temperature conditions. 
2.3 Preparation of stock and standards 
10mg of canagliflozin was accurately weighed and 
transferred to a clean and dry 10ml volumetric flask 
containing 5mlof methanol, sonicated for 1minute and the 
volume is made up to the mark with methanol to obtain a 
final concentration of 1mg/ml. Calibration standards in the 
concentration range of 10-50µg/ml were prepared by 
adequate dilution of the stock solution with 0.02% Formic 
acid as diluent.  
2.4 Method validation 
2.4.1 Specificity 
The specificity of the method was established by 
comparing the chromatograms of drug substance and drug 
product with that of blank and placebo. Absence of peaks 
other than the drug peak such as those of impurities or 
excipients ascertains the specificity of the method. 
2.4.2 Linearity 
Calibration curves were plotted to establish 
linearity of the method by employing five standard 
solutions in the concentration range of 10-50µg/ml each in 
triplicate using an injection volume of 10µl. Statistical 
analysis of the resultant data was performed and parameters 
such as slope, intercept, and regression equation were 
calculated.  
Figure 2: Calibration curve of Canagliflozin 
 
 
 
2.4.3 Precision 
System precision 
It was measured in terms of repeatability of 
application of a homogenous solution by injecting six 
replicates of standard solution (30µg/ml) of drug substance. 
Method precision 
  It was measured in terms of repeatability of 
application by giving six replicates of sample solution of 
drug product, 30µg/ml. In each case, standard deviation and 
percentage relative standard deviation were evaluated to 
ascertain the repeatability of the method. 
2.4.4 Accuracy  
Accuracy of the developed method was confirmed 
by performing standard addition and recovery studies. In 
this method, the sample solution was spiked with known 
concentrations of standard solutions within the linearity 
range at three different levels, 80, 100 and 120% of test 
concentration each in triplicate and analysed. The 
percentage recovery and percentage relative standard 
deviation were tabulated at each level. 
2.4.5 Limit of detection (LOD), limit of quantification 
(LOQ)  
The LOD and LOQ were determined from the 
calibration curve by standard deviation of the response and 
slope method using the formula LOD= 3.3 σ/s and LOQ= 
10 σ/s, where, σ=standard deviation of the intercepts and S= 
mean of slopes obtained in the calibration plots. 
2.4.6 Robustness  
Robustness of the proposed method was 
determined by making small deliberate changes in flow rate 
(±0.2ml/min) and mobile phase (±2%) of the optimized 
method. The deviation in parameters such as tailing factor, 
theoretical plates at each condition was tabulated. 
2.4.7 System suitability 
System suitability of the method was established 
by injecting increasing volumes (10-50µL) of the same 
homogenous standard solution, 30µg/ml. The percentage 
relative standard deviation of retention time, tailing factor 
and theoretical plate number with change in volume was 
evaluated. 
2.4.8 Stability of solution 
Stability of stock solution was determined at a 
temperature of 2-8
o
C by analysing the stock solution at 
regular time intervals   over a period of 24hours. 
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2.5 Assay  
Canagliflozin tablets (Invokana-100mg) were 
taken to estimate the suitability of proposed method to 
estimate Canagliflozin in tablet formulation. For this 20 
tablets were taken, coating was removed, tablets were 
weighed individually to determine the average tablet 
weight. Tablets are then powdered using mortor and pestle, 
the powder equivalent to 10mg of Canagliflozin was 
accurately weighed and transferred into a 10ml volumetric 
flask containing 5ml methanol. The final volume was made 
up to the mark with methanol. The solution was sonicated 
for 1min to ensure solubility of drug. The solution was 
centrifuged for 2min and supernatant was collected, 
adequate dilution was done using 0.02% formic acid obtain 
a sample solution with a final concentration of 30µg/ml. 
The drug content in the formulation was quantified by 
comparing the peak area obtained with that of the standard 
solution. 
 
3. Results and discussion 
Literature survey revealed that there were several 
analytical methods like Spectrophotometry, HPLC, LC-MS, 
LC, GCMS and Only few RP-HPLC methods were reported 
for the estimation of Canagliflozin in bulk and tablet dosage 
forms and these methods used non-volatile buffers which 
reduces column efficiency. Hence the present work aimed 
at the development of a new sensitive, accurate and precise 
RP-HPLC method for the estimation of Canagliflozin in 
bulk and tablet dosage forms and by using mobile phase 
that is compatible with LC-MS. 
3.1 Method development  
Different trials were performed with various 
columns, mobile phase combination and diluents for 
optimum elution of Canagliflozin. Intial trial was carried 
with INERTSIL ODS-3 column (250×4.6mm, 5µ) using a 
mobile phase of 0.02% formic acid and acetonitrile in the 
ratio of  50:50(v/v) at a flow rate of 1ml/min. With these 
LC conditions, Canagliflozin peak was eluted preceding the 
solvent front with a tailing factor (2.45). The mobile phase 
combination was further changed to 40:60(v/v) of 0.02% 
formic acid and acetonitrile at a flow rate of 1ml/min. With 
these LC conditions, the Canagliflozin was eluted as sharp 
peak at 4.43min which showed ideal peak properties. The 
standard chromatogram of Canagliflozin was shown in 
figure.1. 
  The developed method was validated as per ICH 
guidelines. 
3.2 Method validation  
3.2.1 Specificity 
Specificity of the method was as certained from 
the overlay of the standard, sample, blank, placebo 
chromatograms. No interference by the matrix, excipients 
or any other impurities was observed at the elution time of 
Canagliflozin implying the specificity of the method for 
detection of Canagliflozin. 
3.2.2 Linearity 
Linearity was established over a concentration 
range of 10-50µg/mL by plotting a graph of concentration 
versus respective peak areas. Regression analysis of the 
data thus obtained showed a good regression coefficient of 
0.999 with a regression equation y=6292.x-311.6. The 
standard deviation and percentage relative standard 
deviation values were calculated at each concentration 
which were found to be within limits i.e., less than 2. The 
data obtained was shown in table 1. 
3.2.3 Precision 
System and method precision studies were carried 
out by giving six replicate injections of 30µg/mL standard 
solution of drug and sample solution of drug product 
respectively. The data obtained was shown in table 1. The 
percentage relative standard deviation obtained was found 
to be less than 2% for peak areas as per specifications 
3.2.4 Accuracy 
Accuracy of the method was determined by 
employing standard addition method. The amount of 
recovery and percentage relative standard deviation at each 
level i.e., 80, 100 and 120% of test concentration was 
calculated and it was found to be less than 2 percent. The 
accuracy data was represented in table 1.  
Table 1: Linearity, Precision and Accuracy data 
Validation data of Canagliflozin 
Linearity 
Range 
Regression equation 
Regression 
coefficient (R2) 
10-50µg/ml 
Y= 6292.4±311.6 
0.999 
Accuracy 
(n=3) 
Level of Addition 
(percent) 
Mean Recovery 
(RSD) 
 
80 
100 
120 
98.44(0.087) 
99.21(0.040) 
100.31(0.017) 
Precision (n=6) 
System 
Precision 
 
Method 
Precision 
Average Peak area of 
the standard sample 
(RSD) 
189694(0.7622) 
Average peak area of 
the Assay sample 
(RSD) 
188928.33(0.709) 
Percent assay 
(n=3) 
Mean  ± SD 99.57 (0.705) 
 
3.2.5 LOD and LOD 
Limit of detection and limit of quantification 
values were calculated employing the average slope and 
standard deviation ratio method. The LOD and LOQ values 
obtained were 0.00136µg/mL and 0.00414µg/mL 
respectively. 
3.2.6 Robustness  
Robustness studies were carried out by making 
small deliberate changes in the flow rate, (±0.2mL/min) and 
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mobile phase composition (±2%) and %RSD was 
calculated for parameters such as number of theoretical 
plates, tailing factor with respect to the changes were 
tabulated. The results obtained were satisfactory and shown 
in table 2. 
Table 2: Robustness data 
Chromatographic 
parameters 
Retention 
time(min) 
Theoretical 
plates (N) 
Tailing 
factor 
Mobile phase  composition ratio 
(0.02% Formic acid: Acetonitrile) 
42:58 4.749min 7494.864 1.013 
40:60 4.423min 6938.178 1.041 
38:62 4.12min 6932.838 1.063 
Flow rate (mL/min) 
1 5.246min 8290.151 1.041 
1.2 4.423min 6938.178 1.041 
1.4 3.818min 6141.29 1.033 
3.2.7 System suitability   
System suitability testing is an integral part of the 
analytical procedure. System suitability studies were carried 
out by injecting five times a 1µg/mL standard concentration 
of Canagliflozin at different injection volumes ranging from 
10-50µL. The %RSD for system suitability test parameters 
like tailing factor and theoretical plate number were less 
than 2 indicating the present conditions were suitable for 
the analysis of Canagliflozin. 
3.3 Assay  
The percentage assay of the drug in the 
formulation was obtained by comparing the peak areas of 
the sample with that of the standard and they were found to 
be 98.25 respectively. 
3.4 Stability of the analytical solution  
The stability of the stock and standard solution 
were determined by analysis the samples under 
refrigeration (8±1
o 
C) at different time intervals up to 
24hours. The percent variation in assay values at different 
time interval were found to be less than 2 when compared 
with the initial zero time interval solution , thus indicating 
that the solution were stable for a period of 24hours when 
stored at 8
o 
C. 
 
4. Conclusion 
Canagliflozin is an antidiabetic drug used to 
improve glycemic control in patients with type 2 diabetes. 
A sensitive RP-HPLC-PDA method was developed for the 
determination of Canagliflozin in bulk and pharmaceutical 
dosage form with LC-MS compatible mobile phase 
composition in a short run time. The developed method was 
validated as per ICH guidelines (Q2R1) 
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